Keywords: Pfizer, Bosulif, Leukemia, CML, EMA, CHMP, Santhera, Raxone, Optic neuropathy

Good EMA news for Pfizer's Bosulif but not for Santhera's Raxone

Article | 21 January 2013

Print This

Following its monthly meetings last week, the European Medicines Agency the Committee for Medicinal Products for Human Use (CHMP) adopted ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in